Wellington Management Group LLP Sells 153,294 Shares of Inspire Medical Systems, Inc. $INSP

Wellington Management Group LLP reduced its position in Inspire Medical Systems, Inc. (NYSE:INSP) by 6.0% in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 2,382,660 shares of the company’s stock after selling 153,294 shares during the quarter. Wellington Management Group LLP owned 0.08% of Inspire Medical Systems worth $106,290,000 at the end of the most recent quarter.

Other large investors also recently modified their holdings of the company. CWM LLC lifted its position in Inspire Medical Systems by 216.1% in the 4th quarter. CWM LLC now owns 354 shares of the company’s stock worth $33,000 after buying an additional 242 shares during the last quarter. EverSource Wealth Advisors LLC grew its position in Inspire Medical Systems by 1,115.4% during the first quarter. EverSource Wealth Advisors LLC now owns 632 shares of the company’s stock valued at $33,000 after acquiring an additional 580 shares during the last quarter. Havemeyer Place LP bought a new position in Inspire Medical Systems during the fourth quarter valued at approximately $39,000. Smartleaf Asset Management LLC raised its stake in shares of Inspire Medical Systems by 84.0% during the fourth quarter. Smartleaf Asset Management LLC now owns 449 shares of the company’s stock worth $42,000 after acquiring an additional 205 shares in the last quarter. Finally, Versant Capital Management Inc raised its stake in shares of Inspire Medical Systems by 379.0% during the second quarter. Versant Capital Management Inc now owns 958 shares of the company’s stock worth $43,000 after acquiring an additional 758 shares in the last quarter. 94.91% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other news, insider Jason P. Kelly sold 963 shares of the firm’s stock in a transaction dated Friday, August 7th. The shares were sold at an average price of $59.55, for a total value of $57,346.65. Following the completion of the sale, the insider directly owned 18,985 shares of the company’s stock, valued at approximately $1,130,556.75. This trade represents a 4.83% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Company insiders own 2.20% of the company’s stock.

Analysts Set New Price Targets

INSP has been the subject of a number of research reports. Robert W. Baird upped their price objective on shares of Inspire Medical Systems from $54.00 to $59.00 and gave the company a “neutral” rating in a research note on Tuesday, August 4th. Oppenheimer raised shares of Inspire Medical Systems from a “market perform” rating to an “outperform” rating and set a $85.00 price target for the company in a research note on Tuesday, August 4th. Weiss Ratings upgraded shares of Inspire Medical Systems from a “sell (d)” rating to a “sell (d+)” rating in a research report on Wednesday, August 19th. Evercore set a $54.00 price objective on Inspire Medical Systems in a research note on Tuesday, August 4th. Finally, Stifel Nicolaus set a $75.00 price objective on Inspire Medical Systems in a report on Tuesday, August 4th. Two investment analysts have rated the stock with a Strong Buy rating, three have assigned a Buy rating, eleven have issued a Hold rating and three have assigned a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $66.19.

Inspire Medical Systems Stock Performance

INSP opened at $61.67 on Wednesday. Inspire Medical Systems, Inc. has a 52-week low of $38.91 and a 52-week high of $147.03. The stock has a market capitalization of $1.78 billion, a PE ratio of 13.35, a price-to-earnings-growth ratio of 4.79 and a beta of 0.70. The stock’s 50 day moving average price is $53.93 and its 200-day moving average price is $52.32.

Inspire Medical Systems (NYSE:INSP) last announced its quarterly earnings results on Monday, August 3rd. The company reported $0.14 EPS for the quarter, topping analysts’ consensus estimates of ($0.24) by $0.38. The company had revenue of $200.58 million during the quarter, compared to analyst estimates of $194.72 million. Inspire Medical Systems had a return on equity of 8.64% and a net margin of 15.03%.The firm’s revenue was down 7.6% on a year-over-year basis. During the same quarter last year, the firm posted $0.45 earnings per share. Inspire Medical Systems has set its FY 2026 guidance at 1.050-1.450 EPS. Research analysts forecast that Inspire Medical Systems, Inc. will post 1.24 EPS for the current fiscal year.

About Inspire Medical Systems

Inspire Medical Systems, Inc is a medical technology company specializing in implantable neurostimulation devices for the treatment of obstructive sleep apnea (OSA). The company’s flagship offering, the Inspire® system, delivers targeted stimulation of the hypoglossal nerve to maintain airway patency during sleep, providing an alternative therapy for patients who are intolerant of or inadequately managed by continuous positive airway pressure (CPAP) devices.

The Inspire system comprises an implantable pulse generator, a sensing lead that monitors breathing patterns, and a stimulation lead that activates the hypoglossal nerve.